|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5显示文摘Since late 2022, the share of infections caused by the SARS-CoV2 lineage XBB.1.5 has gradually increased in the United States,resulting in XBB.1.5 becoming the dominating SARS-CoV-2lineage in the United States and a similar trend is likely to soontake place also in European countries. However, information onthe virological properties of XBB.1.5 is scarce. Here, weconducted an initial virological assessment of the SARS-CoV-2XBB.1.5 lineage. | Markus Hoffmann Prerna Arora Inga Nehlmeier Amy Kempf Anne Cossmann Sebastian R.Schulz Gema Morillas Ramos Luis A.Manthey Hans-Martin Jäck Georg M.N.Behrens Stefan Pöhlmann | 2023 | Cellular & Molecular Immunology2023，20，4： | 2 |
| 2 | Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods显示文摘Neutralizing antibodies targeting the receptor-binding domain(RBD)of the SARS-CoV-2 spike(S)block severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)entry into cells via surface-expressed angiotensin-converting enzyme 2(ACE2).We used a surrogate virus neutralization test(sVNT)and SARS-CoV-2 S protein-pseudotyped vesicular stomatitis virus(VSV)vector-based neutralization assay(pVNT)to assess the degree to which serum antibodies from coronavirus disease 2019(COVID-19)convalescent patients interfere with the binding of SARS-CoV-2 S to ACE2.Both tests revealed neutralizing anti-SARS-CoV-2 S antibodies in the sera of ~90% of mildly and 100% of severely affected COVID-19 convalescent patients.Importantly,sVNT and pVNT results correlated strongly with each other and to the levels of anti-SARS-CoV-2 S1 IgG and IgA antibodies.Moreover,levels of neutralizing antibodies correlated with the duration and severity of clinical symptoms but not with patient age.Compared to pVNT,sVNT is less sophisticated and does not require any biosafety labs.Since this assay is also much faster and cheaper,sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy. | Berislav Bosnjak Saskia Catherina Stein Stefanie Willenzon Anne Katrin Cordes Wolfram Puppe Gunter Bernhardt Inga Ravens Christiane Ritter Christian R.Schultze-Florey Nina Godecke Jorg Martens Hannah Kleine-Weber Markus Hoffmann Anne Cossmann Mustafa Yilmaz Isabelle Pink Marius M.Hoeper Georg M.N.Behrens Stefan Pohlm ann Rainer Blasczyk Thomas F.Schulz Reinhold Forster | 2021 | Cellular & Molecular Immunology2021，18，4： | 2 |
| 3 | Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2显示文摘The SARS-CoV-2 spike(S)protein engages ACE2 for cell entry,and the S protein/ACE2 interface is an important target for neutralizing antibodies.In the course of the COVID-19 pandemic,SARS-CoV-2 variants have emerged that harbor mutations in the S protein,which confer neutralization resistance and allow viral spread in immunologically nonnaive populations.The most prominent example is the highly mutated Omicron variant,which infects convalescent or vaccinated individuals with unprecedented efficiency[1,2]. | Prerna Arora Amy Kempf Inga Nehlmeier Luise Graichen Sebastian Schulz Anne Cossmann Alexandra Dopfer-Jablonka Martin S.Winkler Hans-Martin Jäck Georg M.N.Behrens Stefan Pöhlmann Markus Hoffmann | 2022 | Cellular & Molecular Immunology2022，19，9： | 0 |
| 4 | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency显示文摘The COVID-19 pandemic,caused by SARS-CoV-2,continues to rage in many countries,straining health systems and economies.Vaccines protect against severe disease and death and are considered central to ending the pandemic.COVID-19 vaccines(and SARS-CoV-2 infection)elicit antibodies that are directed against the viral spike(S)protein and neutralize the virus.However,the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy[1]. | Prerna Arora Cheila Rocha Amy Kempf Inga Nehlmeier Luise Graichen Martin S.Winkler Martin Lier Sebastian Schulz Hans-Martin Jäck Anne Cossmann Metodi V.Stankov Georg M.N.Behrens Stefan Pöhlmann Markus Hoffmann | 2021 | Cellular & Molecular Immunology2021，18，12： | 0 |
| 5 | Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage显示文摘Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies. | Inga Nehlmeier Amy Kempf Prerna Arora Anne Cossmann Alexandra Dopfer-Jablonka Metodi V.Stankov Sebastian R.Schulz Hans-Martin Jäck Georg M.N.Behrens Stefan Pöhlmann Markus Hoffmann | 2023 | Cellular & Molecular Immunology2023，20，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员